PicnicHealth, a health technology company, has unveiled its expansion into the field of oncology and has joined forces with AstraZeneca to establish a registry aimed at generating real-world data pertinent to breast cancer. The company's strategy involves collaborating with individuals battling cancer to compile and organise their medical records data, with the aim of advancing oncology research by harnessing comprehensive datasets.
Additionally, PicnicHealth, has revealed a multiyear collaboration with biopharmaceutical giant AstraZeneca, to establish a registry designed to generate longitudinal real-world data from willing patients in the United States who have been diagnosed with stage 1 to stage 3 breast cancer.
The registry, presently open for patient enrollment, will centralise medical records into a unified platform, enabling patients to contribute de-identified data for breast cancer research.
Dr. Dan Drozd, Chief Medical Officer at PicnicHealth, elaborated on the initiative's rationale: "We're ideally positioned for partners seeking to leverage our expertise in engaging directly with patients to create more comprehensive datasets that provide insights into the patient experience for those with early cancer diagnoses. Given that these patients often have higher survival rates or live with cancer for an extended period, our strength in patient engagement and ability to synthesise patient records across various care facilities, coupled with patient-reported outcomes, aligns well with this endeavour."
Back in April, PicnicHealth announced a partnership with pharmaceutical giant Roche and its subsidiary Genentech. This collaboration aimed to expedite neurological disease research through investments in real-world data. Roche intended to leverage PicnicHealth's datasets concerning Alzheimer’s Disease, related dementias, and myasthenia gravis, a chronic autoimmune disorder resulting in skeletal muscle weakness.
During the same month, the company disclosed its collaboration with the global nonprofit organisation CureDuchenne, dedicated to finding a cure for Duchenne muscular dystrophy. This partnership aimed to strengthen real-world evidence generation for the CureDuchenne Link platform.
In the preceding year, PicnicHealth secured $60 million in Series C funding, following a $35 million equity financing round two years prior.
PicnicHealth has also engaged in a partnership with global biopharmaceutical firm Bristol Myers Squibb, with the objective of merging datasets to enhance the understanding of patients dealing with obstructive hypertrophic cardiomyopathy.
In 2021, PicnicHealth teamed up with Komodo Health to jointly employ their products in constructing a repository of real-world patient data sourced from de-identified information from payers, providers, labs, and electronic health records. This data would then be furnished to biopharmaceutical and academic communities.
Click here to read the original news story.